Good evening :)
$
₹
Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals Ltd

EOCN

PINK
Asset Logo

Galmed Pharmaceuticals Ltd

EOCN

PINK
$3.031.47% (-0.04)
$
₹
$3.031.47% (-0.04)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $3.3M the stock is ranked 6051

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.30
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-15.21
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 1 analyst's reports

Buy
0 analyst
Hold
1 analyst
Sell
0 analyst

Price Upside

+296.04%

Earnings Growth

+43%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Eocene Ltd. was formerly known as Galmed Pharmaceuticals Ltd. and changed its name to Eocene Ltd. in September 2026. Eocene Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Eocene Ltd. was formerly known as Galmed Pharmaceuticals Ltd. and changed its name to Eocene Ltd. in September 2026. Eocene Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
80.45
80.45
1Y Return
24.94%
24.94%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.22
27.22
1Y Return
51.04%
51.04%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.23%
29.23%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
30.37
30.37
1Y Return
23.96%
23.96%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
19.92
19.92
1Y Return
40.01%
40.01%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-20.02Baseline
Forecast for Dec 2026
High$-11.41+43%
Average$-11.41+43%
Low$-11.41+43%

All values in $

20222023202420252026-2,496.97-256.57-73.36-20.02Low+43%Average+43%High+43%
2025
Current$-20.02Baseline
Forecast for Dec 2026
High$-11.41+43%
Average$-11.41+43%
Low$-11.41+43%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-1.8
-4.8
-1.9
-2.7
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue00000
Net Income-2.49-1.89-4.81-1.91-2.72
Net Profit Margin-----
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Galmed Pharmaceuticals Ltd -0.30-
AbbVie Inc80.4550.450.54
Amgen Inc27.2218.782.45
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare EOCN with any stock or ETF
Compare EOCN with any stock or ETF
Comparing from
EOCN
ABBV
AMGN
Loading...

Frequently asked questions

  1. Galmed Pharmaceuticals Ltd (EOCN) share price today is $3.03 as of October 24, 2026 at 1:29 AM IST. The stock touched a day high of $3.41 and a day low of $2.96.

  2. Galmed Pharmaceuticals Ltd stock trades on PINK under the ticker symbol EOCN.

  3. Galmed Pharmaceuticals Ltd's market capitalization is $3.33M as of October 24, 2026 at 1:29 AM IST.

  4. Galmed Pharmaceuticals Ltd's price-to-earnings (P/E) ratio is N/A as of October 24, 2026.

  5. Galmed Pharmaceuticals Ltd's price-to-book (P/B) ratio is 0.30 as of October 24, 2026.

  6. Yes, You can buy Galmed Pharmaceuticals Ltd shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Galmed Pharmaceuticals Ltd shares in three steps: 1. Search Galmed Pharmaceuticals Ltd on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Galmed Pharmaceuticals Ltd trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Galmed Pharmaceuticals Ltd (EOCN) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 3.3003 shares at the current price of $3.03.

Loading...